Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of disease

This publication has 33 references indexed in Scilit:

• Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosis
  Gynecologic Oncology, 1990
• Serum CA 125 in epithelial ovarian cancer. A longitudinal study
  BJOG: An International Journal of Obstetrics and Gynaecology, 1987
• The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
  American Journal of Obstetrics and Gynecology, 1986
• The value of the monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes
  BJOG: An International Journal of Obstetrics and Gynaecology, 1985
• Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer
  American Journal of Obstetrics and Gynecology, 1985
• Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker
  British Journal of Cancer, 1984
• Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen
  American Journal of Obstetrics and Gynecology, 1984
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983
• Antigenic determinants of human placental and testicular placental‐like alkaline phosphatases as mapped by monoclonal antibodies
  European Journal of Biochemistry, 1983
• Long-Term Follow-Up and Prognostic Factors in Ovarian Carcinoma: The Radiumhemmet series 1958 to 1973
  Acta Radiologica: Oncology, 1982